These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1531789)

  • 41. Increased endothelin: nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients.
    Shimada N; Saka S; Sekizuka K; Tanaka A; Takahashi Y; Nakamura T; Ebihara I; Koide H
    Ren Fail; 2003 Jul; 25(4):569-78. PubMed ID: 12911161
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of hemodialysis on intravascular volume and vasoactive hormones.
    Katzarski KS; Randmaa I; Bergström J
    Clin Nephrol; 1999 Nov; 52(5):304-11. PubMed ID: 10584994
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis.
    Kusano E; Inoue M; Akai Y; Furuya H; Ando Y; Tabei K; Asano Y
    Nephron; 2002 Aug; 91(4):654-8. PubMed ID: 12138269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved.
    Ross RP; McCrea JB; Besarab A
    ASAIO J; 1994; 40(3):M880-5. PubMed ID: 8555638
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of dialysis factors and route of administration on response of hemodialysis patients to recombinant human erythropoietin.
    Besarab A; Besarab FM; Miller D
    ASAIO Trans; 1991; 37(3):M181-2. PubMed ID: 1751101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients.
    Vaziri ND; Ritchie C; Brown P; Kaupke J; Atkins K; Barker S; Hyatt J
    ASAIO Trans; 1989; 35(3):505-8. PubMed ID: 2597519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of hematocrit on solute removal during high efficiency hemodialysis.
    Lim VS; Flanigan MJ; Fangman J
    Kidney Int; 1990 Jun; 37(6):1557-62. PubMed ID: 2362408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pressor effect of recombinant human erythropoietin: results of ambulatory blood pressure monitoring and home blood pressure measurements.
    Imai Y; Sekino H; Fujikura Y; Munakata M; Minami N; Hashimoto J; Sakuma H; Watanabe N; Misawa S; Nishiyama A
    Clin Exp Hypertens; 1995 Apr; 17(3):485-506. PubMed ID: 7613524
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of recombinant human erythropoietin on the plasma levels of vasoactive regulatory peptides in patients on maintenance hemodialysis.
    Hegbrant J; Thysell H; Ekman R
    Int J Artif Organs; 1991 Jul; 14(7):411-6. PubMed ID: 1889894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An approach to optimal dialysis using urea kinetic modeling.
    Maeda H; Takahashi S; Inoue M; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):513-22. PubMed ID: 1654471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypertension in patients on chronic hemodialysis: the role of the renin-angiotensin system.
    Igarashi Y; Suzuki H; Imafuku T; Saito I; Saruta T
    Jpn Circ J; 1987 May; 51(5):479-84. PubMed ID: 3306010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level.
    Ulusoy S; Ozkan G; Menteşe A; Yavuz A; Karahan SC; Sümer AU
    Clin Biochem; 2012 Nov; 45(16-17):1444-9. PubMed ID: 22874483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physiological changes during hemodialysis in patients with intradialysis hypertension.
    Chou KJ; Lee PT; Chen CL; Chiou CW; Hsu CY; Chung HM; Liu CP; Fang HC
    Kidney Int; 2006 May; 69(10):1833-8. PubMed ID: 16691262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erythropoetin accelerates hematocrit recovery in post-surgical anemia.
    Atabek U; Alvarez R; Pello MJ; Alexander JB; Camishion RC; Curry C; Spence RK
    Am Surg; 1995 Jan; 61(1):74-7. PubMed ID: 7832387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuroendocrinology of chronic renal failure and renal transplantation.
    Crum R; Fairchild R; Bronsther O; Dominic W; Ward D; Fernandez R; Brown MR
    Transplantation; 1991 Nov; 52(5):818-23. PubMed ID: 1835195
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hormonal mechanisms in blood pressure reduction during hemodialysis in patients with chronic renal failure.
    Masuo K; Mikami H; Ogihara T; Tuck M
    Hypertens Res; 1995 Jun; 18 Suppl 1():S201-3. PubMed ID: 8529063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Circulating levels of renalase, norepinephrine, and dopamine in dialysis patients.
    Zbroch E; Koc-Zorawska E; Malyszko J; Malyszko J; Mysliwiec M
    Ren Fail; 2013; 35(5):673-9. PubMed ID: 23530612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hematocrit increase by mental stress in hypertensive patients.
    Kitahara Y; Imataka K; Nakaoka H; Ishibashi M; Yamaji T; Fujii J
    Jpn Heart J; 1988 Jul; 29(4):429-35. PubMed ID: 2972855
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Does long-term human recombinant erythropoietin (rHuEPO) influence secretion of hormones regulating volume and pressure of arterial blood?].
    Rudka R; Kokot F; Wiecek A; Marcinkowski W; Trembecki J
    Pol Arch Med Wewn; 1994 Aug; 92(2):154-61. PubMed ID: 7800584
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of hemodialysis patients treated with erythropoietin.
    Acchiardo SR; Quinn BP; Moore LW; Burk LB; Miles DE
    Am J Kidney Dis; 1991 Mar; 17(3):290-4. PubMed ID: 1996571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.